Autopsy report · NCT00703339

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

“Lack of enrollment to the trial. Very difficult population to recruit.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 2 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Lung Biotechnology PBC

Sponsor type

Industry

Conditions

Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension

Interventions

Treprostinil sodium for inhalation

Participants

1

Sites

6

Countries

United States

Trials that died the same way

• Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
  “Due to the low recruitment rate since the start of the trial” (78% match in meaning)
• Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
  “Poor trial recruitment” (76% match in meaning)
• Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens
  “Insufficient recruitment population.” (72% match in meaning)
• Using Ultrasound to Predict the Results of Draining Pleural Effusions
  “Difficult to recruit to due to conflicting trials recruiting similar participants.” (71% match in meaning)
• Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
  “The trial is terminated due to the extremely low recruitment rate.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.